Mesoporous Magnesium Carbonate for Stable Amorphous API Loading

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Poorly soluble active pharmaceutical ingredients (APIs) face challenges with insufficient solubility and stability, leading to poor bioavailability and variability in drug exposure, and existing formulation techniques fail to provide long-term stability and patient-friendly dosage forms.

Innovation Solution

A solid, substantially amorphous active pharmaceutical ingredient is formulated with anhydrous and amorphous mesoporous magnesium carbonate (MMC) having specific pore sizes, surface areas, and particle distributions, allowing for high API loads without increasing tablet or capsule size, and maintaining amorphous form during storage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If amorphous forms of drug substances are used to improve solubility and dissolution rate, then bioavailability is improved, but storage stability deteriorates

Engineering Contradiction:

ImprovebioavailabilityVSAvoidstorage stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent uses mesoporous silica as an intermediary carrier material to load the amorphous drug substance. The silica matrix acts as a mediator that protects the amorphous API from crystallization during storage while maintaining its amorphous state for improved solubility and bioavailability when administered.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs mesoporous silica with controlled pore sizes (2-50 nm) to load and stabilize the amorphous drug substance. The porous structure provides a high surface area matrix that can accommodate the API in an amorphous state, preventing crystallization while enabling controlled release and maintaining solubility enhancement.

Inventive Principle:

Principle #31Porous materials

2Quantity of substance

If high API loads are incorporated into formulations to achieve therapeutically sufficient doses, then drug exposure is improved, but tablet or capsule size increases

Engineering Contradiction:

ImproveAPI loadVSAvoidtablet or capsule size

Core Design Contradiction:

Quantity of substanceVSVolume of moving object

Solution Approach 1:

The mesoporous silica carrier provides a high loading capacity due to its large pore volume and high surface area. This allows incorporation of high API loads (up to 50-70% w/w) within a compact particle structure, enabling therapeutically sufficient doses without increasing the overall size of tablets or capsules.

Inventive Principle:

Principle #31Porous materials

Solution Approach 2:

The patent creates a composite material system where the drug substance is loaded into the mesoporous silica matrix. This composite structure combines the therapeutic API with the porous carrier, achieving high drug loading densities that reduce the volume required for delivering therapeutically effective doses.

Inventive Principle:

Principle #40Composite materials

3Reliability

If existing formulation techniques are used to improve drug solubility, then bioavailability may be enhanced, but long term stability and patient compliance deteriorate

Engineering Contradiction:

ImprovebioavailabilityVSAvoidlong term stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent changes the physical parameters of the formulation by using mesoporous silica with specifically controlled pore sizes (2-50 nm) and surface properties. This parameter optimization allows the API to be maintained in an amorphous state with improved solubility while the silica matrix provides long-term stability during storage.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The mesoporous silica acts as an intermediary that simultaneously addresses solubility enhancement and stability requirements. The silica matrix provides a protective environment for the amorphous API, preventing degradation and crystallization over time while maintaining the solubility benefits of the amorphous form.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation achieves therapeutically sufficient API loads with improved solubility and stability, ensuring patient compliance and consistent drug exposure.

Implementation Method 1

particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC)... to stabilize an active pharmaceutical ingredient (API) into a solid and substantially amorphous form

Methodology Applied

Scientific EffectAdsorption: Adsorption

Data Source

PatentUS20260035258A1Novel amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate

Publication Date: 2026.02.05 DISRUPTIVE PHARMA AB

AI summary

The present invention is directed to a solid and substantially amorphous active pharmaceutical ingredient, to an oral pharmaceutical formulation comprising said substantially amorphous active pharmaceutical ingredient, as well as to a method for the manufacture of the same. The invention is also directed to a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC), to a method for the manufacture thereof, and the use of said particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC) to stabilize an active pharmaceutical ingredient (API).